Ergomed Sees 2022 Adjusted Earnings Meeting Market Views; Names New CFO
25 Enero 2023 - 04:29AM
Noticias Dow Jones
By Joe Hoppe
Ergomed PLC said Wednesday that it expects to report an adjusted
Ebitda for 2022 in line with market expectations while revenue
rose, and appointed Jonathan Curtain as incoming chief financial
officer.
The services provider to the pharma industry said revenue for
the year ended Dec. 31 rose 23% to 145.3 million pounds ($179.1
million), meeting market expectations on strong organic and
acquisition-related growth.
The company said it expects adjusted earnings before interest,
taxes, depreciation and amortization--which strips out exceptional
and other one-off items--for 2022 to meet market expectations, but
didn't provide a figure. In 2021, it reported adjusted Ebitda of
GBP25.4 million.
Ergomed's order book grew 23% to around GBP295 million,
"providing excellent forward visibility," it said.
The company said it enters 2023 with a positive outlook,
continuing to take market share and enjoying a resilient
position.
Ergomed also said deputy CFO Mr. Curtain will take over the role
as finance chief on Feb. 3 from Richard Barfield, who intends to
retire. Mr. Curtain joined the company in November, having most
recently held the role of senior vice president of corporate and
commercial finance at ICON PLC.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
January 25, 2023 05:14 ET (10:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024